ProCE Banner Activity

Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE

Slideset Download
Conference Coverage
Subanalysis of phase III RECOURSE trial suggests clinical benefit of TAS-102 in specific patients with metastatic CRC.

Released: June 13, 2016

Expiration: June 12, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals